EGFR and non-small cell lung carcinoma: Despite high initial response rates to first and second generation EGFR-TKIs, eventually all patients with advanced NSCLC harbouring an EGFR mutation will progress on these treatments due to acquired resistance, with a median progression-free survival of 9.7–13.1 months [8, 9].